Filing Flows › ARS Pharmaceuticals (SPRY) › Revenue Under Collaboration Agreements revenue
ARS Pharmaceuticals (SPRY) Revenue Under Collaboration Agreements revenue by quarter
ARS Pharmaceuticals' Revenue Under Collaboration Agreements revenue was $1.7M in Q3 2026 (third quarter 2026), up 29-fold from Q2 2026. Over the last 7 quarters it ranged from $55K (Q3 2025) to $6.9M (Q4 2025).
| Quarter | Revenue Under Collaboration Agreements revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $1.7M | 29× | 30× |
| Q2 2026 | $57K | -98% | -98% |
| Q1 2026 | $2.5M | -64% | 12× |
| Q4 2025 | $6.9M | 125× | — |
| Q3 2025 | $55K | -98% | — |
| Q2 2025 | $2.6M | 12× | — |
| Q1 2025 | $210K | — | — |
Q3 2026 at a glance
ARS Pharmaceuticals, Q3 2026: revenue $37.7M (+16% year over year), operating margin -90.6%, net loss $35.6M, operating cash flow −$33.7M. The chart follows the revenue to costs, profit and cash.
Questions
What is ARS Pharmaceuticals' Revenue Under Collaboration Agreements revenue?
ARS Pharmaceuticals' Revenue Under Collaboration Agreements revenue was $1.7M in Q3 2026 (third quarter 2026), up 29-fold from Q2 2026.
How has ARS Pharmaceuticals' Revenue Under Collaboration Agreements revenue changed?
Over the last 7 quarters it ranged from $55K (Q3 2025) to $6.9M (Q4 2025).